Posted by Michael Wonder on 18 Oct 2025
FDA approves Novo Nordisk's oral semaglutide for cardiovascular risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event
17 October 2025 - In the SOUL trial, oral semaglutide 14 mg reduced the risk of MACE by 14% compared to placebo, in addition to standard therapies.
Novo Nordisk announced today that the US FDA has approved Rybelsus, the only oral GLP-1 medication available, for reducing the risk of major adverse cardiovascular events such as cardiovascular death, heart attack, or stroke in adults with type 2 diabetes who are at high risk for these events, whether they've had a prior cardiovascular event or not (primary and secondary prevention).
